The Nigeria Centre for Disease Control (NCDC) has broken silence over the development of Dexamethsaone as possible treatment for Covid-19.
In a report released Wednesday, NCDC said it was aware of recent outcomes from a UK-Government funded clinical trial for COVID-19.
The results support the use of Dexamethsaone as a possible treatment to reduce the risk of death among COVID-19 patients, who require oxygen or mechanical ventilation.
“Please note that the Government of Nigeria has not validated or approved any treatment for COVID-19. In addition, the use of Dexamethasone for COVID-19 treatment has not been validated by the World Health Organization (WHO)”.
“We are aware of ongoing clinical trials conducted by scientists in the UK and will work with our sister agencies to evaluate this emerging data on the use of Dexamethasone. We will inform the general public on outcomes following scientific review and validation.”
